Literature DB >> 24649082

miR-101 inhibits cell proliferation by targeting Rac1 in papillary thyroid carcinoma.

Xiaojie Lin1, Hongyu Guan1, Hai Li1, Liehua Liu1, Juan Liu1, Guohong Wei1, Zhimin Huang1, Zhihong Liao1, Yanbing Li1.   

Abstract

Accumulating evidence suggests that some microRNAs (miRNAs) are involved in papillary thyroid carcinoma (PTC) progression. However, it remains necessary to elucidate the underlying molecular mechanisms involved. In the present study, we investigated the role of microRNA-101 (miR-101) in PTC via targeting of Ras-related C3 botulinum toxin substrate 1 (Rac1). The results showed that miR-101 was significantly downregulated in PTC tissues compared with adjacent normal tissues. Restoration of miR-101 expression significantly inhibited cell proliferation in the K1 PTC cell line. Moreover, algorithm-based and experimental strategies verified Rac1 as a direct target of miR-101 in the K1 cell line. Taken together, these findings suggest that miR-101 inhibited PTC growth via the downregulation of Rac1 expression, providing a better understanding of miRNA-modulated signaling networks for future cancer therapeutics.

Entities:  

Keywords:  Ras-related C3 botulinum toxin substrate 1; microRNA-101; proliferation; thyroid cancer

Year:  2013        PMID: 24649082      PMCID: PMC3917094          DOI: 10.3892/br.2013.192

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  29 in total

Review 1.  MicroRNAs: synthesis, mechanism, function, and recent clinical trials.

Authors:  Fazli Wahid; Adeeb Shehzad; Taous Khan; You Young Kim
Journal:  Biochim Biophys Acta       Date:  2010-07-07

Review 2.  MicroRNAs and their target gene networks in breast cancer.

Authors:  Elizabeth O'Day; Ashish Lal
Journal:  Breast Cancer Res       Date:  2010-03-19       Impact factor: 6.466

3.  Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age.

Authors:  P E Voutilainen; M M Multanen; A K Leppäniemi; C H Haglund; R K Haapiainen; K O Franssila
Journal:  Thyroid       Date:  2001-10       Impact factor: 6.568

4.  Rho GTPases are over-expressed in human tumors.

Authors:  G Fritz; I Just; B Kaina
Journal:  Int J Cancer       Date:  1999-05-31       Impact factor: 7.396

5.  miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation.

Authors:  Chen-Kai Chou; Rong-Fu Chen; Fong-Fu Chou; Hsueh-Wen Chang; Yi-Ju Chen; Ya-Fang Lee; Kuender D Yang; Jiin-Tsuey Cheng; Chao-Cheng Huang; Rue-Tsuan Liu
Journal:  Thyroid       Date:  2010-05       Impact factor: 6.568

6.  RAC1b overexpression in papillary thyroid carcinoma: a role to unravel.

Authors:  Ana Luísa Silva; Francisca Carmo; Maria João Bugalho
Journal:  Eur J Endocrinol       Date:  2013-04-29       Impact factor: 6.664

7.  ARF1 controls Rac1 signaling to regulate migration of MDA-MB-231 invasive breast cancer cells.

Authors:  Sebastian Lewis-Saravalli; Shirley Campbell; Audrey Claing
Journal:  Cell Signal       Date:  2013-05-23       Impact factor: 4.315

8.  Abnormal expression of p120-catenin, E-cadherin, and small GTPases is significantly associated with malignant phenotype of human lung cancer.

Authors:  Yang Liu; Yan Wang; Yong Zhang; Yuan Miao; Yue Zhao; Peng-Xin Zhang; Gui-Yang Jiang; Jun-Yi Zhang; Yang Han; Xu-Yong Lin; Lian-He Yang; Qing-Chang Li; Chen Zhao; En-Hua Wang
Journal:  Lung Cancer       Date:  2009-01-21       Impact factor: 5.705

9.  Expression and significance of Rac1, Pak1 and Rock1 in gastric carcinoma.

Authors:  Yong-jun Wu; Yi Tang; Zhen-feng Li; Zheng Li; Yi Zhao; Zhen-jiang Wu; Qi Su
Journal:  Asia Pac J Clin Oncol       Date:  2013-01-08       Impact factor: 2.601

10.  MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1.

Authors:  Rui Wang; Hong-Bin Wang; Chan Juan Hao; Yi Cui; Xiao-Chen Han; Yi Hu; Fei-Feng Li; Hong-Fei Xia; Xu Ma
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

View more
  20 in total

1.  MicroRNA-409-3p suppresses cell proliferation and cell cycle progression by targeting cyclin D2 in papillary thyroid carcinoma.

Authors:  Zhijun Zhao; Fei Yang; Yan Liu; Kai Fu; Shanghua Jing
Journal:  Oncol Lett       Date:  2018-08-01       Impact factor: 2.967

Review 2.  The role of miRNAs in the pheochromocytomas.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen
Journal:  Tumour Biol       Date:  2015-10-13

3.  MicroRNA-101 suppresses migration and invasion via targeting vascular endothelial growth factor-C in hepatocellular carcinoma cells.

Authors:  Zhenyu Liu; Jingjie Wang; Yuqing Mao; Bing Zou; Xiaoming Fan
Journal:  Oncol Lett       Date:  2015-10-27       Impact factor: 2.967

4.  MiR-101 targets USP22 to inhibit the tumorigenesis of papillary thyroid carcinoma.

Authors:  Huadong Zhao; Haili Tang; Qike Huang; Bo Qiu; Xiaomin Liu; Dong Fan; Li Gong; Hang Guo; Chong Chen; Shixiong Lei; Lu Yang; Jianguo Lu; Guoqiang Bao
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

5.  Nanoparticle delivery of miR-223 to attenuate macrophage fusion.

Authors:  Laura Beth Moore; Andrew J Sawyer; Jennifer Saucier-Sawyer; W Mark Saltzman; Themis R Kyriakides
Journal:  Biomaterials       Date:  2016-02-26       Impact factor: 12.479

6.  Down-regulation of miR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer.

Authors:  Dengfeng Li; Wei Jian; Chuankui Wei; Hongming Song; Yifan Gu; Yi Luo; Lin Fang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 7.  MicroRNA expression profiles in the management of papillary thyroid cancer.

Authors:  James C Lee; Justin S Gundara; Anthony Glover; Jonathan Serpell; Stan B Sidhu
Journal:  Oncologist       Date:  2014-10-16

8.  Cancer stem cells as a potential therapeutic target in thyroid carcinoma.

Authors:  Luisa Vicari; Cristina Colarossi; Dario Giuffrida; Ruggero De Maria; Lorenzo Memeo
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

9.  miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells.

Authors:  Ye Lei; Bin Li; Shiyu Tong; Lin Qi; Xiheng Hu; Yunbo Cui; Zengbo Li; Wei He; Xiongbing Zu; Zhi Wang; Minfeng Chen
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

10.  A proteomics analysis to evaluate cytotoxicity in NRK-52E cells caused by unmodified Nano-Fe₃O₄.

Authors:  Yi-Reng Lin; Chao-Jen Kuo; Hugo You-Hsien Lin; Chin-Jen Wu; Shih-Shin Liang
Journal:  ScientificWorldJournal       Date:  2014-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.